Global Influenza Antiviral Drugs Market Research Report contains strategic analysis of top grooming companies of the Influenza Medication market. The report reveals the emerging trends, market growth drivers, shares, revenue, and CAGR. It helps to understand the current and future growth of the market with restraints and opportunities. This report is aimed at guiding people towards an apprehensive, finer, and comprehensible knowledge of the market. The analysts have studied in the report about the different regions such as North America, Europe, and the Asia Pacific based on production, revenue, and sales.
According to the research report, “Global Influenza (Flu) Antiviral Drugs Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027”, influenza, also known as flu, is a respiratory disease caused by an influenza virus. Fever, cough, sore throat, cold are some of the common symptoms of the disorder. In temperate zones, this disease primarily occurs during winters while in tropical regions influenza may occur throughout the year. Severe complications of influenza can also develop a disease like pneumonia. For instance, in 2021, Gilead Sciences has signed licensing agreement with pharmaceutical manufacturers such as Cipla Ltd., Hetero Labs Ltd., Dr. Reddy’s Laboratories Ltd., Mylan, and others to expand the supply of antiviral medicines.
Over the forecast period, the demand for antiviral drugs is growing due to the increasing viral infections across the globe. The global influenza medications market is divided into hospitals, clinics, pharmacies, and others. According to a study, an estimated million people are living with hepatitis infection and out of these, around half of the million have chronic hepatitis C virus infection. However, the prevalence of viral diseases has led to a striving growth in the market. Abbvie, Novartis AG, Gilead Sciences, Mylan N.V., Glaxo Smith, Kline Merck & Co., Janssen Pharmaceuticals, Bristol-Myers Squibb Company, are some of the prominent key players operating in the antiviral drugs market.
Request For Sample Report- https://kenresearch.com/sample-report.php?Frmdetails=NDQ0NzIw
In 2021, the market was valued at USD Million and is projected to reach to significant value in USD Million by the end of 2027. Moreover, the growth rate for the worldwide market is expected to grow at a single-digit CAGR by 2027. This growth is attributable to the presence of various key pharmaceutical companies in the U.S. In Latin America, the governments of Mexico and Brazil are taking persistent initiatives to manage viral infections, eventually increasing the generic pharmaceutical companies in the sector. On the other hand, countries such as India and Japan are establishing supply networks and enhancing pharmaceutical industries to accelerate the growth in this region.
The outbreak of the COVID-19 pandemic has positively affected the industry globally. The treatment of coronavirus has increased the demand for b antiviral drugs at a large scale. Remdesivir, favipiravir, oseltamivir, and other combination medicines are highly prescribed for the treatment of COVID-19. Moreover, governments, all over the world, are increasing funding to pharmaceutical companies to develop novel therapeutics against COVID-19.
Increasing collaborations for the development and manufacturing of antiviral drugs are expected to result in the development of a high number of novel drugs in the coming years. The presence of strong pipeline drugs for diseases like HIV will also fuel market growth over the forecast period. The key enterprises present in the market are constantly striving to bring about new treatment options for patients suffering from viral infections. Increasing approval and expected commercialization of novel medicines for viral infections are anticipated to drive market growth.
For More Information, refer to below link:-
Global Augmented Reality Automotive Market Research Report
Related Reports
Follow Us
LinkedIn | Instagram | Facebook | Twitter | YouTube
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
